Gilead Sciences' Sovaldi Patent Application Rejected In India By: Benzinga via Benzinga January 14, 2015 at 13:08 PM EST Gilead Sciences, Inc. (NASDAQ: GILD) patent application for its hepatitis C drug Sovaldi was rejected by the Indian patent office ... Read More >> Related Stocks: Gilead Sciences